TIDMACPH
This announcement contains regulated information for the
purposes of Article 7 of the Market Abuse Regulation (EU) No
596/2014.
Cambridge, UK and Indianapolis, US -- 15 March 2022: Acacia
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company")
(EURONEXT: ACPH), a hospital pharmaceutical company focused on the
development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures or cancer chemotherapy,
was notified on 11 March 2022 that the Company's Employee Benefit
Trust ("EBT") intends to subscribe for 63,710 new ordinary shares
in the Company at their par value of 2p each and at an aggregate
cost to the EBT of GBP1,274.20 (the "New Ordinary Shares"). The
Company has agreed to lend GBP1,274.20 to the EBT to fund its
subscription for the New Ordinary Shares.
The New Ordinary Shares to be held in the EBT will be
transferred to Michael Bolinder, the Company CEO, to satisfy the
share awards granted in 2018 under the Company's Performance Share
Plan (the "Awards"). The Awards vested on 17 December 2021 and must
be settled by 15 March 2022 pursuant to the terms of the Awards and
the Company's Performance Share Plan.
Accordingly, on 15 March 2022, the Company allotted the New
Ordinary Shares to the EBT and such shares will rank pari passu in
all respects with the existing ordinary shares of the Company.
Application has been made to Euronext Brussels for the admission of
the New Ordinary Shares to trading.
Following the issue of the New Ordinary Shares, the Company's
total issued share capital consists of 100,923,133 ordinary shares
with one voting right per share. The Company does not hold any
ordinary shares in treasury. Therefore, following the issue of the
New Ordinary Shares, the total number of voting rights in the
Company is 100,923,133.
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Frazer Hall, Mark Swallow, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 MEDiSTRAVA Consulting
mailto:IR@acaciapharma.com IR@acaciapharma.com +44 20 7638 9571
mailto:acaciapharma@medistrava.com
acaciapharma@medistrava.com
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 mailto:chrisvanraemdonck@telenet.be
mailto:ikoffler@lifesciadvisors.com chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Barhemsys(R) (amisulpride) injection is a selective dopamine (D2
and D3) receptor antagonist approved and available in the US for
the treatment and prevention of postoperative nausea & vomiting
(PONV) in adult patients.
Please see full prescribing information, including Important
Safety Information, at
https://www.globenewswire.com/Tracker?data=kAnqlMfjIbCwbxQ1dCjm6M8k2sT4_oA9PsHsqueVoDciM4qSYZEF-FSVDiO5GmYF_7f_LbzwjfpvSyw3wKHTEosK6mvDlOfaUzF2i6JaUEzq7RJR7PuQYNzQEInOu1UmkUeplJ3Arym_1rmz_2lpu1_DRsOfVDHzolcEBk3MzlNKssUQYWNJzWC2EiJNNkOU8xojrDTjEYxupD5s6p_xjrxTsHHH06Thji5arsR_m7Co1F93FX6JmtKhHZAHoDBoUUSaZFKW3kINoL1MRt-ILX-bX-CwjTi7Rr4IAEpUNSpgLIge50lZzF0lSInGiWWub6u5BlrUGPJmLbks2hNSKGVQy4PCuMEiIi6mpeJo-BjMn43IM6nHv8rIMBOoqCPhtwSphPta45NQe4wWWlrVe6lYJUpVo0cRHQ1n7oPkfbc_kHgf81naRhT9cocIk4RH
www.BARHEMSYS.com.
Byfavo(R) (remimazolam) for injection, is an IV benzodiazepine
sedative approved and available in the US for the induction and
maintenance of procedural sedation in adults undergoing procedures
lasting 30 minutes or less. Byfavo is in-licensed from Paion UK
Limited for the US market.
Please see full prescribing information, including Important
Safety Information and Boxed Warning, at
https://www.globenewswire.com/Tracker?data=kAnqlMfjIbCwbxQ1dCjm6K_YadcPGpfXLBLFUZ27ueKo3GKQS4XTFmUTDMuqPv4e_tpFJLKCXmDAz41Wkhfhuhc4d-ZtAbupldbWgi6KtxU_zxv9oWJWrkF1-2BntokMCIp0XXmgiydN5MVVPSDZHjzjqBC5tml7rIYQ6qpglGQwglLb9ERyGcBSgat-PjvlVQngybwGhdeJfAV9Mv0-jTO03CPyb3fGTtE1x7vAO27K1wiuPo2fYUlkEBJG-vJBMU4xv0FdZxcg935skDuewRIGL9KiBuKXR1gF1E5NGzWVhHu6RZTJchdgpFdOYGMvGX8pNHLsxXk5l0cwqXh0bgscB30eyApyaJAjLzlziSreZYIORfw6sQsIVVIsptop_CdbgBSF2HHu-vYe0L9UbeyYyiJbURmTSlcXKXfULIE=
www.BYFAVO.com.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centred in Cambridge, UK. The Company is
listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
This release is intended for investors and media only.
https://www.globenewswire.com/Tracker?data=kAnqlMfjIbCwbxQ1dCjm6EaiXUVEZp1-r60qbYWdNwRqgHczr9T7-GHKl-AuumYRdGXR9DhtraEPTr_VStCkWH9l4JgDan_hW-z_57kmsgnmD9tzGZrcrMq7VMxMYUOUBNF5S52sPREoB6fXwttz2ypnGSKrzeGokvXtGu811WRndk6QMI23Otpj-Eum6_axpv8R77KORF22G6uTh2h0x7mF6n8klEuQMXStF7V-iCD-5XLUiSeBNVzrsN3UPgcZhAHg_nn4EhtYeuZJ4LW7GA==
www.acaciapharma.com
Forward looking statements
This announcement includes forward-looking statements, which are
based on current expectations and projections about future events.
These statements may include, without limitation, any statements
preceded by, followed by or including words such as "believe",
"expect", "intend", "may", "plan", "will", "should", "could" and
other words and terms of similar meaning or the negative thereof.
Forward-looking statements may and often do differ materially from
actual results. These forward-looking statements are subject to
risks, uncertainties and assumptions about the Company and its
subsidiaries and investments, including, among other things, the
development of its business, trends in its operating industry, and
future capital expenditures and acquisitions. By their nature,
forward-looking statements involve risk and uncertainty because
they relate to future events and circumstances. Any forward-looking
statements reflect the Company's current view with respect to
future events and are subject to risks relating to future events
and other risks, uncertainties and assumptions relating to the
Group's business, results of operations, financial position,
prospects, growth or strategies and the industry in which it
operates. Save as required by law or applicable regulation, the
Company and its affiliates expressly disclaim any obligation or
undertaking to update, review or revise any forward-looking
statement contained in this announcement whether as a result of new
information, future developments or otherwise. Forward-looking
statements speak only as of the date they are made.
(END) Dow Jones Newswires
March 15, 2022 13:07 ET (17:07 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Acacia Pharma (LSE:0PNT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024